Indian Pharma Market growth in chronic therapy rapidly in April 7.4%, dominance of domestic companies continues

In April 2025, the Indian Pharma Market (IPM) recorded a growth of 7.4% on an annual basis. The biggest reason for this boom was the increase in demand for treatment of chronic therapy such as heart, CNS (Central Nervous System) and Respiratory.

Both acute and chronic treatment performed better

In April, the sales of drugs associated with acute treatment i.e. seasonal diseases increased by 6% growth. At the same time, an annual increase of 9% in chronic treatment medicines, which indicates good recovery in the past. In March 2025, the growth of the pharma market was 9.3%, while in April 2024 it was 9%.

Prices of medicines, new launch and volume help in growth

In April 2025, in an annual growth of IPM, three factor played a big role. The prices of the two contributed 4.3%, the new launch contributed 2.3% and volume growth i.e. more drugs were contributed to 1.3%.

Strong gains in cardiac, gastro, chemotherapy and urology segment

Some special segments saw tremendous growth. Growth of 11.3% in the cardiac segment, 9.4% in gastro, chemotherapy drugs i.e. 12.6% in anticancer drugs and 13.1% in urology.

Domestic companies perform better than multinational companies

In April 2025, domestic pharma companies performed better than multinational companies (MNCs). Indian companies stake in IPM 83%, while the rest of the stake was with MNCs. In March too, the growth rate of Indian pharma companies was 7.4%, which was equal to MNCs but she was far ahead in terms of market share.